Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

INCLUSION CRITERIA: * No deleterious germline BRCA1 or BRCA2 mutation based on full sequencing and comprehensive rearrangement testing at an external reference laboratory; patients with variants of unknown significance will be eligible * Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 * Must have progressed on at least 1 prior chemotherapy regimen for the treatment of advanced breast cancer; there is no upper limit on the number of prior therapies * If prior platinum agent (eg, carboplatin or cisplatin) has been administered, no evidence of progression, or within 8 weeks of stopping platinum treatment * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT ≤ 5 x ULN * Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's syndrome) * Calculated creatinine clearance ≥ 30 mL/min or serum creatinine ≤ 1.5 mg/dL * Hemoglobin ≥ 9.0 g/dL with last transfusion at least 14 days before day 1 of study drug * Absolute neutrophil count (ANC) ≥ 1500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Able to take oral medications * Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures * Sexually active patients of childbearing potential must be wil…